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ABSTRACT
Objective: The objective was to improve the bioavailability, stability of formulation, and skin permeability of Duloxetine HCl.
Method: Microemulsion was prepared with oleic acid as oil, water, and Smix ratio of tween 20 to propylene glycol (1:3). Pseudo-ternary phase diagrams 
were constructed to determine the region of existence of microemulsions prepared using oil titration method. Optimization of formulations was done 
based on the in vitro diffusion studies. The microemulsion was gelled using carbopol 934p and HPMCK 100 as the gelling agent.
Result: After the analysis of different evaluation parameter and drug release, the F3 batch was selected as a promising formulation for delivery of 
duloxetine HCl as a microemulsion gel for transdermal drug delivery with 79.607% drug release in 10 h.
Conclusion: It was observed that transdermal microemulsion gel can be formulated successfully for duloxetine HCl with improved bioavailability. 
Among the other batches, the F3 batch was selected as an optimized batch because all the evaluation parameters results are satisfactory. From 
stability data, the formulation was found to be stable as no phase separation or turbidity was observed in the formulation after 3 months.
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INTRODUCTION
Transdermal drug delivery offers many advantages over other 
traditional routes; however, the barrier nature of the skin made 
it difficult for most of the drugs to be delivered through it [1]. 
Transdermal drug delivery system has several advantages such as 
ability to deliver the drug into systemic circulation by avoiding first-
pass metabolism, avoids drug degradation in the gastrointestinal 
tract, and improves bioavailability [2]. A remarkably broad range of 
transdermal formulations is available, ranging from simple solutions 
and lotions, though commonly used creams, ointments, gels, and 
patches. While selecting a suitable dosage form drug, physicochemical 
properties such as solubility, pKa, and lipophilicity must be taken 
into consideration [3-5]. Duloxetine HCl (Fig. 1) [N-methyl-γ-(1-
naphthyloxy)-2-thiophenepropylamine] is a selective serotonin and 
noradrenaline reuptake inhibitor, approved by the USFDA for the 
treatment of major depressive disorders [6]. Microemulsion gel, as the 
name suggests they are the combination of microemulsion and gel. The 
term “microemulsion” refers to a thermodynamically stable, isotropic 
clear dispersion of two immiscible liquids, such as oil and water, 
which is stabilized by an interfacial film of surfactant and cosurfactant 
molecules [7]. In fact, the presence of a gelling agent in the water 
phase converts a classical emulsion into a microemulsion-based gel. 
The direct oil-in-water system is used to entrap lipophilic drugs, 
whereas hydrophilic drugs are encapsulated in the reverse water-in-
oil system. Microemulsions possess a certain degree of elegance and 
are easily washed off whenever desired. They also have a high ability 
to penetrate the skin.
MATERIALS AND METHODS
Duloxetine HCl was a gift sample from CTX Life science Pvt. Ltd., Gujarat. 
HPMCK100, Propylene glycol, NaOH were procured from Chemdyes 
Corporation, Gujarat. Carbopol 934p and oleic acid were procured from 
Research Lab Finchem, India. Tween 20 was procured from Encore 
Chemicals. Methanol was procured from Thomas Baker Pvt. Ltd., India. 
All reagents used were of analytical grade.
Methods
Solubility studies [8-11]
The solubility of duloxetine HCl was determined in various excipients 
such as oils, surfactant, and cosurfactant. Excess amount of 
duloxetine HCl was added to 2 ml of each excipient and vortex-mixed. 
They were stirred in a rotary shaker at 37±0.5°C. All samples were 
centrifuged at 3000 RPM for 15 min using a laboratory centrifuge. 
The supernatant was filtered, suitably diluted with methanol, and 
analyzed spectrophotometrically at λmax of 290 nm using a Double 
beam UV-Visible spectrophotometer.
Construction of ternary phase diagram [12]
Pseudoternary phase diagrams comprises oil, Smix, and water 
were developed using the oil titration method, specific ratio of Smix 
(1:1,1:2,1:3,2:1, and 3:1), water were taken in test tubes and vortexed 
for 5 min followed by addition of oil with a micropipette, the addition 
of oil was continued until addition of one more drop produce turbidity. 
They were also visually observed for phase clarity and flowability. 
The volume of oil phase was noted, and phase diagrams were then 
constructed using chemix software.
Formulation of microemulsions [13]
The microemulsion formulations were prepared using oleic acid 
as oil phase, Tween 20 as a surfactant and propylene glycol as 
cosurfactant based on the solubility studies, as the drug was having 
the highest solubility in these solvents. The ratios were selected from 
the constructed pseudo-ternary phase diagrams. Using the oil phase 
titration method microemulsions were prepared. Microemulsions 
were prepared by mixing the surfactant mixture and aqueous phase 
at the constant stirring rate. The drug was added to the oil phase, and 
methanol was added to enhance the solubility of drug in oil phase, 
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followed by dropwise addition of oil phase to aqueous phase at constant 
stirring rate until microemulsions were formed.
Formulation of microemulsion gels
Microemulsions were prepared, and then HPMC K100 and Carbopol 
934p were added to it. This mixture was then kept for soaking to 24 h. 
Next day pH of the gels was adjusted using NaOH solution. Compositions 
of duloxetine HCl loaded microemulsion gels are given in Table 1.
Characterization of microemulsion gel
Appearance
The prepared formulation was inspected visually for their color, 
appearance, and consistency.
pH
The pH values of formulations were measured by a pH meter. The pH 
meter was calibrated before each use with buffer solution of pH 4.0, 7.0, 
and 9.0. The measurement of pH of the formulation was done [14].
Viscosity
The viscosities of formulations were measured with a Brookfield 
Viscometer DV–II+PRO, equipped with spindle no. LV1 and spindle code 
61. The spindle was dipped in the preparation and rotated at ambient 
temperature at 100 RPM for 5 min [15].
Globule size and zeta potential
The mean droplet size and zeta potential were determined by photon 
correlation spectroscopy using the Zetasizer (Malvern Instruments, 
UK). Each sample was diluted to a suitable concentration with filtered 
double-distilled water. Globule size analysis was performed at 25°C with 
an angle of detection at 90°C. Size and zeta potential of formulations 
were obtained directly from the instrument [14].
Spreadability
Two glass slides were taken, and onto one slide, an excess of 3 g of 
gel was placed. Then, another glass slide was placed such that gel 
sandwiched between two glass slides. The top slide was subjected to 
a stress of 50 g by putting weight on it. Then, the time (in seconds) 
required by the gel to travel a distance of 10 cm was noted. A shorter 
time interval indicates better spreadability [13].
Fig. 1: Duloxetine HCl drug structure
Fig. 2: Solubility of drug in different oils
Fig. 3: Solubility of drug in surfactants
Fig. 4: Solubility of drug in cosurfactants
Fig. 5: Phase diagram of oleic acid in different ratios of Tween 20 and propylene glycol
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In-vitro drug release studies [13]
Drug release studies were performed using Franz diffusion cell employing a 
Millipore membrane (Millipore membrane 0.45 µm). Millipore membrane 
was initially soaked in pH 7.4 phosphate buffer solution for 24 h. It was 
then clamped between the donor and receptor compartments of the Franz 
diffusion cell. The receptor compartment was filled with pH 7.4 phosphate 
buffer solution and was magnetically stirred throughout the experiment 
at 100 RPM. The donor compartment contained an appropriate amount 
(2 g) of the formulation. Aliquots (1 ml) of sample were withdrawn 
from the receptor compartment at specified time intervals for 10 h and 
were replaced with fresh buffer solution to maintain sink conditions. 
The samples were analyzed for drug concentration using UV-Visible 
double beam spectrophotometer at 289 nm. The drug concentration was 
calculated using the standard calibration curve.
Release kinetics of optimized batch [16]
Model-dependent methods are based on different mathematical 
functions, which describe the dissolution profile. Mathematical 
modeling aids in predicting the drug release rates and diffusion 
behavior of these systems by the solution of an appropriate model, 
thereby reducing the number of experiments needed. The model-
dependent approaches included as follows;
• Zero-order kinetic models.
• First-order kinetic model.
• Higuchi model.
• Korsmeyer–Peppas model (the power law).
• Hixson–Crowell model.
Stability studies [17,18]
The optimized batch is subjected to stability studies at 30°C±2°C 
at 65% RH±5% RH for duration of 3 months. Stability of the stored 
formulations was evaluated by visually inspecting the formulations for 
phase separation or turbidity.
RESULTS AND DISCUSSION
Solubility studies
Solubility of drug in different oils
The solubility of duloxetine HCl in various oils was analyzed to select oil 
for microemulsions.
The maximum amount of drug was found to be dissolved in oleic 
acid, i.e., 10 mg/ml. Hence oleic acid was selected as oil phase for the 
formulation. As shown in Fig. 2.
Fig. 8: Cumulative % drug release of F1- F3 formulation
Fig. 6: Globule size of optimized batch F3
Fig. 7: Zeta potential of optimized batch F3
Table 1: Composition of microemulsion gel formulation
Ingredients F1 F2 F3
Duloxetine HCl 0.115 g 0.4 g 1.1 g
Oleic acid 11.5 ml 11.1 ml 9 ml
Tween 20: PG (1:3) 55.7ml 58 ml 63.6 ml
Water 33 ml 31 ml 27.3 ml
Methanol - 1 ml 1 ml
HPMC K100 0.6 g 0.6 g 0.6 g
Carbopol 934p 1 g 1 g 1 g
NaOH q.s. q.s. q.s.
Total 100 g 100 g 100 g
Table 2: Evaluation of Microemulsion gel
Sr.No. Parameters F1 F2 F3
1. Appearance Off-white Off-white Off-white
2. pH 6.59 6.23 6.72
3. Viscosity (cp) 19.2 20.6 22.2
4. Globule size (nm) 269 263 260
5. Zeta potential (mV) −58.2 −60.1 −64.8
6. Spreadability (s) 40 37 34
Table 3: In vitro drug release of F1-F3 formulation shows 
percentage of cumulative drug release
Time (h) F1 F2 F3
1 2.19±0.27 2.82±0.47 4.073±0.27
2 2.82±0.24 3.52±0.47 4.464±0.23
3 5.25±0.36 6.34±0.71 8.302±0.75
4 8.85±0.49 10.65±0.72 13.627±1.02
5 13.71±0.59 16.14±1.06 20.053±1.44
6 20.13±1.06 23.50±1.41 27.967±1.65
7 27.81±1.42 32.28±1.80 37.840±2.05
8 36.75±1.53 42.86±2.03 49.753±2.10
9 47.79±1.67 55.55±2.18 63.543±2.81
10 60.64±1.77 70.05±2.62 79.607±3.77
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Solubility of dug in surfactants
The solubility of duloxetine HCl in various surfactants was analyzed to 
select surfactant for microemulsions.
The maximum amount of drug was found to be dissolved in Tween 
20, i.e. 132 mg/ml. Hence, Tween 20 was selected as surfactant for the 
formulation. As shown in Fig. 3.
Solubility of drug in cosurfactants
The solubility of duloxetine HCl in various cosurfactants was analyzed 
to select cosurfactant for microemulsions.
The maximum amount of drug was found to be dissolved in propylene 
glycol, i.e., 234 mg/ml. Hence, propylene glycol was selected as 
cosurfactant for the formulation. As shown in Fig. 4.
Construction of ternary phase diagram
Fig. 5 represents the pseudo-ternary phase diagrams of oleic acid with 
various ratios of Tween 20 and propylene glycol. It was found that the 
area of microemulsion became enlarged as the Smix reached (1:3) ratio. 
Characterization of microemulsion gel
Physical appearance
The prepared gels were checked for their color, appearance, and 
consistency and were having a smooth, homogenous texture and off-
white appearance. As shown in Table 2.
pH
The pH of the formulations was found to be between 6.23 and 6.72. The 
results are shown in Table 2.
Viscosity
The viscosity of all three batches was measured using Brookfield 
Viscometer DV–II+PRO. The results are shown in Table 2.
Table 4: Release kinetics of optimized batch F3
Batch no. Zero-order First order Higuchi Kors. Meyer peppas Hix. crow Best-fit model
F3 0.9236 0.7769 0.7379 0.9375 0.9407 Hix. crow
Fig. 9: (a-e) Release kinetic study of optimized batch F3
Table 5: Stability studies at 30°C±2°C at 65% RH±5% RH for 3 
month
Parameters 1 month 2 month 3 month
Appearance Off-white Off-white Off-white
pH 6.71 6.70 6.71
Viscosity (cp) 21.8 21.9 22.1
Globule size (nm) 261 260 260
Zeta potential (mV) -64.7 -64.6 -64.7
Spreadability (s) 35 34 34
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Globule size and zeta potential
The globule size and zeta potential were measured for all three 
batches. F3 batch showed optimum result. As shown in Table 2 and 
Figs. 6 and 7. Figs. 6 and 7 show particle size distribution and zeta 
potential of the formulation F3. The particle size of the microemulsion 
gel was found to be 260 nm, and zeta potential was found to be 
−64.8 mV which indicates that the particles of microemulsion gel 
are negatively charged which provide electrostatic stabilization. The 
polydispersity index was found to be 0.594 which indicates narrow 
particle size distribution.
Spreadability
Spreadability of the formulations was determined. The results were 
shown in Table 2, indicating that the optimal gel formulations have 
shown good spreadability in <1 min.
In vitro drug release of F1-F3 formulation shows percentage of 
cumulative drug release
Drug release studies were performed using Franz diffusion cell 
employing a Millipore membrane. pH 7.4 phosphate buffer was used 
as the release medium. Drug release was found to be the highest for 
the formulation F3 (79.607%) at 10th h. As shown in Table 3 and 
Fig. 8.
Among all the batch, batch F3 showed a significant release as compared 
to other formulations.
Release kinetics of optimized batch
The Release kinetics of optimized batch F3 were studied, and the F3 
batch showed higher correlation with Hixon–Crowell. The result was 
shown in Fig. 9 and Table 4.
Stability studies
The optimized batch was kept for stability studies at 30°C±2°C at 65% 
RH±5% RH for 3 months. As shown in Table 5.
CONCLUSION
The study demonstrated that the microemulsion gel formulation 
can be employed to improve the stability of formulation and skin 
permeability of duloxetine HCl. Microemulsion was prepared with 
oleic acid as oil, water, and Smix ratio of TWEEN 20: PG (1:3). F3 was 
found to be stable with the globule size of 260 NM and percentage 
of drug release was found to be 79.607% in 10 h using carbopol 
934p and HPMC K100 as the gelling agent. It can be concluded that 
microemulsion gel can be formulated successfully for duloxetine HCl 
with improved bioavailability. From stability data, the formulation was 
found to be stable as no phase separation or turbidity was observed in 
the formulation after 3 month.
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